Gliosarcoma clinical trials at UC Cancer

1 research study open to eligible people

Showing trials for

  • DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

    open to eligible people ages 18 years and up

    This phase II trial studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to bevacizumab in patients with glioblastoma that has come back. DSC-MRI may help evaluate changes in the blood vessels within the cancer to determine a patient?s response to treatment.

    at UC Irvine

Our lead scientists for Gliosarcoma research studies include .